**Confirmation of HLA Typing**

<table>
<thead>
<tr>
<th>Registry Use Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence Number:</td>
</tr>
<tr>
<td>Date Received:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CIBMTR Center Number:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CIBMTR Research ID:</td>
<td></td>
</tr>
<tr>
<td>Event date:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>YYYY MM DD</td>
</tr>
</tbody>
</table>

**Product Identifiers:**

| Registry donor ID: |    |
| Non-NMDP cord blood unit ID: |    |
| Global Registration Identifier for Donors (GRID): |    |
| ISBT DIN:           |    |
| Registry or UCB Bank ID: |    |
| Donor DOB:          |    |
|                       | YYYY MM DD |
| Donor Age:          |    |
|                      | [ ] Months (use only if less than 1 year old) |
| Donor Sex:          |    |
|                      | [ ] Male | [ ] Female |

OMB No: 0915-0310
Expiration Date: 08/31/2025

Public Burden Statement: The purpose of this data collection system is to provide technical assistance and share expertise with health care organizations, health care providers and health care networks interested in implementing telehealth technology. The resource centers serve as focal points for advancing the effective use of telehealth technologies in their respective communities and regions. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0915-0310 and it is valid until 08/31/2025. Public reporting burden for this collection of information is estimated to average 0.27 hours per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 14N136B, Rockville, Maryland, 20857 or paperwork@hrsa.gov.
Donor / Cord Blood Unit Identification

This form must be completed for all non-NMDP allogeneic or syngeneic donors or recipients, or non-NMDP cord blood units. If the donor, recipient, or cord blood unit was secured through the NMDP, then report HLA typing on the appropriate NMDP forms.

A separate copy of this form should be completed for each non-NMDP donor, recipient, or cord blood unit.

1. Specify the person for whom this typing is being done:
   - [ ] Recipient — final typing
   - [ ] Donor

HLA Typing by DNA Technology

2. Was documentation submitted to the CIBMTR? (e.g. lab report)
   - [ ] Yes
   - [ ] No

**HLA Alleles Defined by DNA Technology** (e.g., Sequence Specific Oligonucleotide Probe (SSOP) typing, Sequence Specific Primer (SSP) typing or Sequence Based (SBT) typing.)

DNA technology can be used to type for a single allele, combinations of alleles (allele strings) or a “generic” allele designation which is similar to a serologic typing result. For this reason, the number of digits, as well as the number of alleles, for reporting will vary.

Laboratories may use “/”, “–” or a combination of numbers and letters on the typing report as a shorthand notation for the results. Transcribe the information onto the form as directly as possible. The letters are called allele codes, and will be 1 or more characters in length which represent a combination of possible alleles at a locus. The same allele combination may be reported several different ways (e.g., DRB1*01:01 or 01:02, DRB1*01:01/01:02, DRB1*01:01/02, or DRB1*01:AB).

There will be two alleles reported for each locus, unless the individual is presumed homozygous (i.e., carries two copies of the same allele) at a locus. Transcribe the first allele designation in the first box, and the second allele designation in the second box. If the person is homozygous, leave the second box blank.

Class I

3. Locus A
   - [ ] Known – **Go to question 4**
   - [ ] Unknown – **Go to question 5**

4. First A* allele designations
5. Locus B
   - Known – Go to question 6
   - Unknown – Go to question 7

6. First B* allele designations

   Second B* allele designations

7. Locus C
   - Known – Go to question 8
   - Unknown – Go to question 9

8. First C* allele designations

   Second C* allele designations

Class II

9. Locus DRB1
   - Known – Go to question 10

CIBMTR Form 2005 R7 (page 3 of 19). Form Released 23 Sep 2022. Last Updated 23 Sep 2022.
Copyright © 2022 NMDP and The Medical College of Wisconsin, Inc. All rights reserved.
CIBMTR Center Number: ___ ___ ___ ___ ___  CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

□ Unknown – Go to question 11

10. First DRB1* allele designations

Second DRB1* allele designations

Class II (Optional)

Please provide the optional allele information if it is available from your laboratory.

11. Locus DRB3
   □ Known – Go to question 12
   □ Unknown – Go to question 13

12. First DRB3* allele designations

Second DRB3* allele designations

13. Locus DRB4
   □ Known – Go to question 14
   □ Unknown – Go to question 15

14. First DRB4* allele designations
15. Locus DRB5
   □ Known – Go to question 16
   □ Unknown – Go to question 17

16. First DRB5* allele designations

Second DRB5* allele designations

17. Locus DQB1
   □ Known – Go to question 18
   □ Unknown – Go to question 19

18. First DQB1* allele designations

Second DQB1* allele designations

19. Locus DPB1
   □ Known – Go to question 20
   □ Unknown – Go to question 21

20. First DPB1* allele designations
### Second DPB1* allele designations

<table>
<thead>
<tr>
<th>Locus DQA1</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Known – <a href="#"><em>Go to question 22</em></a></td>
</tr>
<tr>
<td>- Unknown – <a href="#"><em>Go to question 23</em></a></td>
</tr>
</tbody>
</table>

### First DQA1* allele designations

<table>
<thead>
<tr>
<th>Locus DPA1</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Known – <a href="#"><em>Go to question 24</em></a></td>
</tr>
<tr>
<td>- Unknown – <a href="#"><em>Go to question 25</em></a></td>
</tr>
</tbody>
</table>

### First DPA1* allele designations

<table>
<thead>
<tr>
<th>Locus DPB1</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Known – <a href="#"><em>Go to question 26</em></a></td>
</tr>
<tr>
<td>- Unknown – <a href="#"><em>Go to question 27</em></a></td>
</tr>
</tbody>
</table>

---

**Antigens Defined by Serologic Typing**
Use the following lists when reporting HLA-A and B antigens. Report broad antigens only when your laboratory was not able to confirm typing for a known split antigen.

Instructions for the use of the “X” Antigen Specificity for Typing By Serology

Each HLA locus has a serologically defined “X” antigen specificity: AX, BX, CX, DRX, DPX, and DQX. At this time an “X” specificity is defined as “unknown but known to be different from the other antigen at that locus.” This is different from a blank specificity, which is defined as “unknown but assumed to be the same as the other antigen at that locus.” When comparisons between recipient and donor antigens involve an “X” or “blank” specificity, the “X” or “blank” is assumed to be homozygous for the antigen reported at the locus. In other words, the search algorithm treats typings containing “blank” or “X” antigens in the same manner as known homozygous typings.
A Antigens

25. Number of antigens provided:
   - One – **Go to question 26, then continue with question 28**
   - Two – **Go to questions 26-27**

26. Specificity – 1st antigen
   - A1
   - A2
   - A203
   - A210
   - A3
   - A9
   - A10
   - A11
   - A19
   - A23(9)
   - A24(9)
   - A2403
   - A25(10)
   - A26(10)
   - A28
   - A29(19)
   - A30(19)
   - A31(19)
   - A32(19)
   - A33(19)
   - A34(10)
   - A36
   - A43
   - A66(10)
   - A68(28)
   - A69(28)
   - A74(19)
   - A80
   - AX
27. Specificity – 2nd antigen

- A1
- A2
- A203
- A210
- A3
- A9
- A10
- A11
- A19
- A23(9)
- A24(9)
- A2403
- A25(10)
- A26(10)
- A28
- A29(19)
- A30(19)
- A31(19)
- A32(19)
- A33(19)
- A34(10)
- A36
- A43
- A66(10)
- A68(28)
- A69(28)
- A74(19)
- A80
- AX
B Antigens

28. Number of antigens provided:
   - One – Go to question 29, then continue with question 31
   - Two – Go to questions 29-30

29. Specificity – 1st antigen
   - B5
   - B7
   - B703
   - B8
   - B12
   - B13
   - B14
   - B15
   - B16
   - B17
   - B18
   - B21
   - B22
   - B27
   - B2708
   - B35
   - B37
   - B38(16)
   - B39(16)
   - B3901
   - B3902
   - B40
   - B4005
   - B41
   - B42
   - B44(12)
   - B45(12)
   - B46
   - B47
   - B48
30. Specificity – 2nd antigen

- B5
- B7
- B703
- B8
- B12
- B13
- B14
- B15
- B16
- B17
- B18
- B21
- B22
- B27
- B2708
- B35
- B37
- B38(16)
- B39(16)
- B3901
- B3902
- B40
- B4005
- B41
- B42
- B44(12)
- B45(12)
- B46
- B47
- B48
- B49(21)
- B50(21)
- B51(5)
- B5102
- B5103
CIBMTR Center Number: _______ _______ _______ _______ _______ _______ _______ _______ _______ _______ _______ _______

CIBMTR Research ID: _______ _______ _______ _______ _______ _______ _______ _______ _______ _______ _______ _______ _______ _______

☐ B52(5)
☐ B53
☐ B54(22)
☐ B55(22)
☐ B56(22)
☐ B57(17)
☐ B58(17)
☐ B59
☐ B60(40)
☐ B61(40)
☐ B62(15)
☐ B63(15)
☐ B64(14)
☐ B65(14)
☐ B67
☐ B70
☐ B71(70)
☐ B72(70)
☐ B73
☐ B75(15)
☐ B76(15)
☐ B77(15)
☐ B78
☐ B81
☐ B82
☐ BX
Optional Antigen Reporting

Please provide the following optional antigen information if it is available from your laboratory.

Antigens Defined by Serologic Typing

C Antigens

31. Number of antigens provided:
   - □ One – Go to question 32, then continue with question 34
   - □ Two – Go to questions 32-33

32. Specificity – 1st antigen
   - □ Cw1
   - □ Cw2
   - □ Cw3
   - □ Cw4
   - □ Cw5
   - □ Cw6
   - □ Cw7
   - □ Cw8
   - □ Cw9(w3)
   - □ Cw10(w3)
   - □ CX

33. Specificity – 2nd antigen
   - □ Cw1
   - □ Cw2
   - □ Cw3
   - □ Cw4
   - □ Cw5
   - □ Cw6
   - □ Cw7
   - □ Cw8
   - □ Cw9(w3)
   - □ Cw10(w3)
   - □ CX
Bw Specificity

34. Specificity Bw4 present?
   - Yes
   - No

35. Specificity Bw6 present?
   - Yes
   - No

DR Antigens

36. Number of antigens provided:
   - One – Go to question 37, then continue with question 39
   - Two – Go to questions 37-38

37. Specificity – 1st antigen
   - DR1
   - DR103
   - DR2
   - DR3
   - DR4
   - DR5
   - DR6
   - DR7
   - DR8
   - DR9
   - DR10
   - DR11(5)
   - DR12(5)
   - DR13(6)
   - DR14(6)
   - DR1403
   - DR1404
   - DR15(2)
   - DR16(2)
   - DR17(3)
   - DR18(3)
38. Specificity – 2nd antigen

- DR1
- DR103
- DR2
- DR3
- DR4
- DR5
- DR6
- DR7
- DR8
- DR9
- DR10
- DR11(5)
- DR12(5)
- DR13(6)
- DR14(6)
- DR1403
- DR1404
- DR15(2)
- DR16(2)
- DR17(3)
- DR18(3)
- DRX

**DR51 Antigen**

39. Specificity DR51 present?

- Yes
- No
DR52 Antigen

40. Specificity DR52 present?
   ☐ Yes
   ☐ No

DR53 Antigen

41. Specificity DR53 present?
   ☐ Yes
   ☐ No

DQ Antigens

42. Number of antigens provided:
   ☐ One – Go to question 43, then continue with question 45
   ☐ Two – Go to questions 43-44

43. Specificity – 1st antigen
   ☐ DQ1
   ☐ DQ2
   ☐ DQ3
   ☐ DQ4
   ☐ DQ5(1)
   ☐ DQ6(1)
   ☐ DQ7(3)
   ☐ DQ8(3)
   ☐ DQ9(3)
   ☐ DQX
44. Specificity – 2nd antigen
   - DQ1
   - DQ2
   - DQ3
   - DQ4
   - DQ5(1)
   - DQ6(1)
   - DQ7(3)
   - DQ8(3)
   - DQ9(3)
   - DQX

**DP Antigens**

45. Number of antigens provided:
   - One – *Go to question 46, then continue with signature line*
   - Two – *Go to questions 46-47*

46. Specificity – 1st antigen
   - DPw1
   - DPw2
   - DPw3
   - DPw4
   - DPw5
   - DPw6
   - DPX

47. Specificity – 2nd antigen
   - DPw1
   - DPw2
   - DPw3
   - DPw4
   - DPw5
   - DPw6
   - DPX